ArticleCritical care (London, England)2020
Assessment of pulmonary surfactant in COVID-19 patients.
Article in Critical care (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- A therapy for suppressing canonical and noncanonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Adsorption of pulmonary and exogeneous surfactants on SARS-CoV-2 spike protein.Journal of colloid and interface science · 2023Article
- Management of severe neonatal respiratory distress due to vertical transmission of severe acute respiratory syndrome coronavirus 2: a case report.Journal of medical case reports · 2022Article
- Reduced levels of pulmonary surfactant in COVID-19 ARDS.Scientific reports · 2022Article
- Anti-inflammatory effects of GLP-1 in patients with COVID-19.Expert review of anti-infective therapy · 2022Review
- Pulmonary surfactant and COVID-19: A new synthesis.QRB discovery · 2022Article
- Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components.Frontiers in immunology · 2022Review
- Roles of steroid receptors in the lung and COVID-19.Essays in biochemistry · 2021Review
- Alveolar type II cells and pulmonary surfactant in COVID-19 era.Physiological research · 2021Review
- Phospholipids dock SARS-CoV-2 spike protein via hydrophobic interactions: a minimal in-silico study of lecithin nasal spray therapy.The European physical journal. E, Soft matter · 2021Article
- Non-destructive vacuum-assisted measurement of lung elastic modulus.Acta biomaterialia · 2021Article
- The Role of Alveolar Edema in COVID-19.Cells · 2021Review
- Article
- Pneumothorax in otherwise healthy non-intubated patients suffering from COVID-19 pneumonia: a systematic review.Journal of thoracic disease · 2021Review
- Breath-Synchronized Nebulized Surfactant in a Porcine Model of Acute Respiratory Distress Syndrome.Critical care explorations · 2021Article
- Article
- The Role of Pulmonary Surfactants in the Treatment of Acute Respiratory Distress Syndrome in COVID-19.Frontiers in pharmacology · 2021Review
- Coronavirus-Induced Host Cubic Membranes and Lipid-Related Antiviral Therapies: A Focus on Bioactive Plasmalogens.Frontiers in cell and developmental biology · 2021Review
- Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome.Respiratory medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.